<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21573">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01747512</url>
  </required_header>
  <id_info>
    <org_study_id>DX-CPERT-002</org_study_id>
    <nct_id>NCT01747512</nct_id>
  </id_info>
  <brief_title>An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)</brief_title>
  <official_title>A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc
      Pertechnetate in a cyclotron unit.  A study done at the Cross Cancer Institute in 2011 with
      ten patients using this imaging agent showed that it was safe and produced images with the
      same pattern as generator produced Pertechnetate.  This study is now being done in larger
      numbers of patients to again show that the imaging pattern of both agents is the same, and
      to again demonstrate its safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate the efficacy of cyclotron-produced Tc-99m pertechnetate (C-PERT; manufactured
      by the Edmonton PET Centre/ERC) in comparison to generator-produced Tc-99m pertechnetate
      (G-PERT; from approved commercial source; using qualitative and quantitative clinical
      imaging biodistribution data.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>To demonstrate the efficacy of C-PERT (manufactured by the Edmonton PET Centre/ERC) in comparison to G-PERT (fromm approved commercial sources) using qualitative and quantitative clinical imaging biodistribtion data.</measure>
    <time_frame>5 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of C-PERT from adverse event data</measure>
    <time_frame>5 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Thyroid Neoplasms</condition>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>C-PERT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>45 patients with cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-PERT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>65 patients with cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-PERT</intervention_name>
    <description>Patients with thyroid and Head and Neck cancer</description>
    <arm_group_label>C-PERT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-PERT</intervention_name>
    <description>Patients with thyroid and Head and Neck cancer</description>
    <arm_group_label>G-PERT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  thyroid cancer, or

          -  Head and Neck cancer for salivary gland transfer

          -  age 18-79

          -  biochemical parameters &lt; 5x ULN

          -  WBC &gt; 3.0/uL

          -  ANC &gt; 1.5/uL

          -  platelets &gt; 75,000/uL

          -  hemoglobin &gt; 10 g/dL

          -  Karnofsky 50-100

        Exclusion Criteria:

          -  nursing or pregnant females

          -  &lt; 18 or  &gt; 79 Years

          -  uncontrolled asthma

          -  acute iritis

          -  narrow angle glaucoma

          -  previous radiation to head/neck
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AJB McEwan, MB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, Cross Cancer Institute, Cancer Care, Alberta Health Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marg Landon</last_name>
      <phone>780 432-8751</phone>
    </contact>
    <contact_backup>
      <last_name>Merlita Lamadrid</last_name>
      <phone>780 432-8751</phone>
    </contact_backup>
    <investigator>
      <last_name>AJB McEwan, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>December 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>99mTc Pertechnetate</keyword>
  <keyword>thyroidectomy</keyword>
  <keyword>thyroid neoplasms</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
